felin
haemoplasma
haemotrop
mycoplasm
bacteria
mycoplasma
haemof
mhf
pathogen
often
induc
haemolyt
anaemia
immunocompet
cat
whilst
candidatu
mycoplasma
haemominutum
cmhm
candidatu
mycoplasma
turicensi
usual
caus
anaemia
unless
concurr
diseas
immunosuppress
present
tasker
et
al
tasker
subclin
carrier
state
also
exist
presenc
infect
confirm
haemoplasmosi
caus
clinic
sign
tasker
acut
phase
respons
apr
part
innat
immun
respons
characteris
chang
serum
acut
phase
protein
app
concentr
et
al
use
diagnost
therapeut
biomark
et
al
griebsch
et
al
mitchel
et
al
measur
app
wide
use
human
medicin
berbari
et
al
patel
et
al
sage
et
al
increas
interest
use
companion
anim
eckersal
although
date
limit
studi
carri
cat
harvey
gaskin
duthi
et
al
kajikawa
et
al
sasaki
et
al
paltrinieri
et
al
paltrinieri
et
al
b
tamamoto
et
al
tamamoto
et
al
author
knowledg
studi
evalu
apr
haemoplasmosi
cat
report
elev
haptoglobin
hp
concentr
six
anim
experiment
infect
mhf
harvey
gaskin
aim
present
studi
characteris
apr
experiment
infect
mhf
cmhm
measur
serum
concentr
three
app
serum
amyloid
saa
haptoglobin
hp
glycoprotein
agp
influenc
chronic
felin
immunodefici
viru
fiv
infect
apr
haemoplasma
infect
also
assess
studi
perform
serum
sampl
obtain
previou
research
tasker
et
al
b
fig
procedur
experi
describ
undertaken
project
licens
approv
uk
anim
scientif
procedur
act
briefli
studi
use
specif
pathogen
free
spf
deriv
cat
one
four
group
n
case
group
b
publish
elsevi
ltd
infect
cmhm
group
x
mhf
administ
ml
heparinis
blood
iv
cmhmor
mhfinfect
donor
cat
group
x
chronic
infect
month
fiv
strain
cat
clinic
normal
studi
commenc
three
cat
group
randomli
select
given
marbofloxacin
marbocyl
mgkg
oral
daili
day
day
postinfect
pi
cmhminfect
cat
cat
number
day
pi
mhfinfect
cat
cat
number
tasker
et
al
b
differ
time
treatment
reflect
differ
time
cours
infect
mhfinfect
cat
treat
earli
cours
infect
anaemia
present
cmhminfect
cat
subclin
infect
treat
later
cours
infect
cmhm
copi
number
remain
high
group
receiv
marbofloxacin
treatment
order
evalu
respons
haemoplasma
spp
cat
given
subcutan
fluid
therapi
lactat
ringer
solut
pcv
fell
andor
anim
exhibit
evid
dehydr
serum
sampl
collect
preinfect
day
weekli
day
pi
exclud
day
pi
fortnightli
day
pi
serum
amyloid
concentr
determin
use
immunoturbidimetr
method
use
human
valid
cat
hansen
et
al
glycoprotein
concentr
measur
use
rapid
immunoturbidimetr
assay
valid
use
cat
benc
et
al
haptoglobin
concentr
determin
use
commerci
avail
kit
tridelta
develop
ltd
saa
concentr
measur
first
follow
agp
hp
concentr
although
inadequ
amount
serum
avail
analys
app
sampl
group
seven
sampl
analys
hp
three
analys
agp
group
b
four
sampl
assess
hp
agp
group
x
five
two
sampl
analys
hp
agp
respect
group
one
sampl
examin
hp
agp
data
enter
valid
within
databas
excel
microsoft
export
spss
softwar
version
analysi
signific
set
p
statist
analysi
perform
app
concentr
measur
pretreat
ensur
confound
effect
treatment
assess
effect
chronic
fiv
infect
apr
haemoplasma
infect
mannwhitney
u
test
use
compar
app
concentr
pi
fivinfect
nonfivinfect
anim
cmhm
mhf
assess
effect
infect
apr
mean
app
concentr
pi
day
cmhm
day
mhf
respect
compar
preinfect
day
valu
use
wilcoxonsign
rank
test
convent
twotail
test
use
assess
chang
hp
agp
concentr
saa
preinfect
concentr
detect
limit
saa
concentr
chang
pi
investig
use
onetail
test
analys
carri
use
nonparametr
test
due
small
sampl
size
twoway
repeat
measur
anova
perform
app
day
pi
pretreat
measur
avail
cmhm
mhf
use
fiv
haemoplasma
spp
group
variabl
residu
analysi
test
satisfactorili
normal
homogen
varianc
confirm
suitabl
test
preexist
fiv
infect
significantli
affect
saa
concentr
follow
cmhm
mhf
infect
hp
concentr
follow
cmhm
infect
agp
concentr
follow
mhf
infect
tabl
therefor
saa
concentr
data
cmhminfect
group
b
mhfinfect
group
x
cat
hp
data
cmhminfect
group
b
cat
agp
data
mhfinfect
group
x
cat
combin
analys
fiv
infect
howev
affect
hp
concentr
follow
mhf
infect
fivinfect
cat
significantli
greater
hp
concentr
nonfivinfect
anim
tabl
fiv
infect
also
affect
agp
concentr
follow
cmhm
infect
fivinfect
cat
significantli
lower
agp
concentr
nonfivinfect
anim
tabl
thu
hp
concentr
mhfinfect
cat
group
x
agp
concentr
cmhminfect
cat
group
b
analys
separ
day
pi
follow
cmhm
infect
cat
demonstr
rise
saa
concentr
fig
peak
concentr
day
pi
mean
saa
concentr
significantli
elev
day
pi
compar
day
tabl
return
baselin
level
one
cmhminfect
cat
day
pi
prior
marbofloxacin
treatment
serum
amyloid
concentr
cat
return
baselin
level
day
pi
increas
saa
concentr
detect
mhfinfect
cat
fig
concentr
peak
around
day
pi
mean
saa
concentr
significantli
elev
day
pi
compar
day
tabl
marbofloxacin
treatment
associ
decreas
saa
concentr
mhfinfect
cat
eg
other
eg
concentr
aap
start
decreas
prior
treatment
twoway
anova
detect
interact
effect
fiv
haemoplasma
infect
saa
concentr
f
p
day
pi
howev
mhfinfect
cat
significantli
higher
mean
saa
concentr
mgl
compar
cmhminfect
anim
mgl
f
p
fiv
infect
statu
signific
effect
f
p
variabl
increas
hp
concentr
occur
cmhminfect
cat
day
pi
mean
concentr
significantli
differ
day
pi
compar
day
valu
fig
tabl
time
marbofloxacin
treatment
commenc
day
pi
hp
concentr
alreadi
declin
cmhminfect
cat
mhfinfect
anim
demonstr
increas
decreas
hp
concentr
baselin
level
day
pi
fig
c
mean
hp
concentr
significantli
differ
day
pi
nonfivinfect
fivinfect
cat
compar
day
tabl
although
trend
hp
concentr
decreas
follow
mhf
infect
observ
fivinfect
cat
haptoglobin
concentr
fell
day
pi
onward
day
pi
cat
concentr
preinfect
level
marbofloxacin
treatment
increas
rate
declin
twoway
anova
show
signific
differ
hp
concentr
mhfand
cmhminfect
cat
day
pi
f
p
effect
fiv
statu
f
p
effect
interact
factor
f
p
tabl
statist
analysi
data
infect
haemoplasma
spp
acut
phase
protein
app
compar
nonfivinfect
fivinfect
cat
pre
day
post
haemoplasmainfect
respect
refer
interv
given
app
statist
signific
result
highlight
bold
median
rang
measur
group
app
signific
differ
found
fivinfect
nonfivinfect
cat
data
combin
comparison
preand
posthaemoplasmainfect
data
day
pi
cmhm
infect
associ
significantli
differ
agp
concentr
either
fivinfect
nonfivinfect
cat
compar
day
valu
fig
b
tabl
small
fluctuat
agp
concentr
occur
throughout
studi
treat
untreat
cmhminfect
cat
variat
seen
nonfivinfect
cat
day
pi
cmhm
infect
mhf
infect
associ
variabl
agp
concentr
vari
peak
fluctuat
evid
throughout
one
cat
develop
mark
elev
concentr
aap
day
pi
fig
significantli
higher
mean
agp
concentr
record
day
pi
follow
mhf
infect
compar
day
tabl
twoway
anova
demonstr
signific
differ
agp
concentr
mhfand
cmhminfect
cat
day
pi
f
p
although
signific
approach
mhfinfect
cat
exhibit
larger
agp
concentr
gl
cmhminfect
cohort
gl
interact
effect
model
found
signific
f
p
although
signific
effect
fiv
statu
detect
f
p
author
knowledg
first
studi
comprehens
evalu
apr
cat
infect
haemoplasma
spp
given
serum
analys
obtain
previou
studi
investig
haemoplasmachron
fiv
infect
tasker
et
al
b
concurr
system
viral
infect
could
confound
effect
result
glycan
moieti
agp
shown
modifi
cat
subclin
terminallyinfect
fiv
pocacqua
et
al
present
studi
lower
agp
concentr
found
fivinfect
compar
nonfivinfect
anim
follow
cmhm
infect
higher
hp
concentr
occur
fivinfect
compar
nonfivinfect
cat
infect
mhf
howev
result
statist
signific
measur
group
cat
remain
within
refer
interv
number
group
small
result
contrast
duthi
et
al
app
measur
singl
timepoint
six
cat
termin
fivassoci
diseas
studi
found
cat
agp
hp
concentr
refer
interv
respect
mark
increas
agp
found
acut
phase
viral
infect
felin
coronaviru
paltrinieri
et
al
although
decreas
app
follow
viral
infect
either
acut
chronic
describ
patient
human
immunodefici
viru
hiv
infect
mani
app
eg
creactiv
protein
crp
hp
fibrinogen
higher
compar
nonhivinfect
control
jahoor
et
al
treiting
et
al
delangh
et
al
elev
concentr
app
particularli
crp
associ
increas
mortal
opportunist
diseas
pneumocysti
jirovecii
pneumonia
nixon
landay
sage
et
al
aid
patient
crp
part
felin
apr
et
al
author
knowledg
studi
compar
apr
hiv
fiv
infect
serum
sampl
taken
preand
immedi
postfiv
infect
cat
current
studi
avail
analysi
beyond
scope
studi
rais
saa
concentr
observ
follow
infect
haemoplasma
spp
evid
cat
day
pi
previous
describ
cat
urinari
tract
disord
postsurgeri
kajikawa
et
al
sasaki
et
al
saa
concentr
usual
return
close
preinfect
valu
day
pi
consist
selflimit
apr
despit
sustain
circul
haemoplasma
copi
number
tasker
et
al
b
find
indic
elev
saa
concentr
haemoplasmainfect
cat
suggest
acut
day
postexposur
rather
chronic
infect
infect
mhf
associ
significantli
higher
saa
concentr
cmhm
infect
consist
mhf
pathogen
foley
et
al
westfal
et
al
tasker
et
al
tasker
et
al
haematolog
variabl
previous
assess
cat
tasker
et
al
b
mhfinfect
cat
develop
regen
macrocyt
hypochrom
haemolyt
anaemia
day
pi
rapid
increas
saa
observ
anim
day
pi
therefor
mirror
develop
anaemia
although
mhf
infect
associ
significantli
greater
saa
concentr
infect
cmhm
latter
also
associ
signific
increas
saa
confirm
induct
apr
cmhm
albeit
lower
magnitud
inde
tasker
et
al
found
cmhm
infect
result
decreas
pcv
cat
onethird
anim
decreas
point
anaemia
concentr
saa
also
correl
diseas
sever
felin
pancreat
tamamoto
et
al
decreas
mirror
clinic
improv
current
studi
fact
treatment
instig
apr
maxim
andor
clinic
sign
appar
may
explain
lack
associ
saa
concentr
treatment
found
haptoglobin
concentr
chang
significantli
follow
either
cmhm
mhf
infect
signific
differ
concentr
biomark
cmhm
mhf
infect
trend
hp
concentr
decreas
follow
mhf
infect
seen
among
fivinfect
cat
perhap
circul
hp
complex
haemoglobin
hershko
et
al
caus
transient
decreas
hp
haemolysi
previous
report
experiment
infect
cat
harvey
gaskin
reason
identifi
fivinfect
cat
remain
unknown
fiv
infect
associ
sever
haemolysi
follow
intercurr
mhf
infect
tasker
et
al
concentr
agp
significantli
elev
albeit
highli
variabl
degre
individu
acut
mhf
acut
cmhm
infect
possibl
due
pathogen
natur
mhf
thu
agp
may
less
sensit
indic
felin
apr
saa
sinc
infect
mhf
cmhm
associ
signific
increas
saa
like
particular
app
differ
sensit
respond
differ
diseas
process
case
saa
creactiv
protein
human
kidney
allograft
reject
casl
et
al
although
author
knowledg
comparison
sensit
saa
agp
felin
apr
carri
saa
increas
peak
earlier
agp
hp
follow
experimentallyinduc
inflamm
kajikawa
et
al
retrospect
natur
current
studi
result
number
limit
serum
sampl
volum
suffici
facilit
analysi
three
app
sampl
statist
power
elimin
variat
individu
respons
limit
rel
small
number
anim
group
number
would
reduc
treat
untreat
cat
compar
treatment
period
mhfand
cmhminfect
cat
differ
limit
statist
analysi
differ
two
infect
haemoplasma
spp
frequent
sampl
acut
infect
apr
maxim
eg
daili
day
pi
may
provid
greater
statist
power
facilit
daili
statist
comparison
kajikawa
et
al
instead
data
point
record
within
period
statist
analysi
perform
mean
app
concentr
pi
infect
haemoplasma
final
apr
cat
natur
occur
fiv
haemoplasma
spp
infect
may
differ
experiment
infect
anim
differ
diseas
transmiss
andor
exposur
pathogen
may
import
context
although
data
analys
statist
present
studi
still
provid
valuabl
inform
longterm
chang
app
follow
haemoplasma
infect
antibiot
treatment
studi
demonstr
mhf
cmhm
despit
differ
pathogen
associ
apr
infect
cat
although
app
nonspecif
indic
inflamm
infect
measur
may
facilit
differenti
acuteclin
chronicsubclin
haemoplasma
infect
saa
found
particular
promis
context
rise
higher
follow
mhf
cmhm
infect
rapidli
return
baselin
level
acut
phase
infect
none
author
paper
financi
person
relationship
peopl
organis
could
inappropri
influenc
bia
content
paper
